Hopkinton, MA, Feburary 16, 2022
– Phosphorex & Dolomite experts Dr. Julia Rashba-Step, Dr. Cate O’Brien, Dr. Nicholas Boylan and Dr. Nicholas Karabin, as they share their insights about the most important considerations when making liposomes and lipid nanoparticles (LNPs) with microfluidics.
Interest in nanotechnology, including both polymeric and lipidic nanoparticles, has grown significantly in the last decade. The tremendous success of mRNA-lipid nanoparticle (LNP)-based vaccines during the COVID-19 pandemic has led to further explosive growth in development and created new opportunities in this area. The unprecedented speed of development of the COVID-19 LNP-based vaccines was, to a large extent, built upon foundational work performed over the last 10–15 years in LNP platform development.
This is why Phosphorex and Dolomite partnered to bridge their complementary areas of expertise: Phosphorex brings extensive expertise and capabilities in nanoparticle-based formulations, analytical characterization, process development, scale-up, and manufacturing. Phosphorex has developed a comprehensive approach to optimize the LNP development process and streamline transition into clinical manufacturing.
Dolomite Microfluidics leverages 20 years of industry-leading Microfluidics technology, product engineering and applications knowledge to design and manufacture cutting-edge particle generation platforms, such as the Automated Nanoparticle (ANP) System enabling customers to fast-track their own product development processes.
Session 1: Tuesday, March 1st, 2022 Time: 14:00 GMT | 09:00 EST | 06:00 PST Event type: Webinar – Live
Session 2: Tuesday, March 8th, 2022 Time: 09:00 PST | 12:00 EST | 17:00 GMT Event type: Webinar – Live
Please click here to register for the event